Skip to main content
Fig. 2 | BMC Medicine

Fig. 2

From: Maximizing the cost-effectiveness of cervical screening in the context of routine HPV vaccination by optimizing screening strategies with respect to vaccine uptake: a modeling analysis

Fig. 2

Cost-effectiveness of guideline-based screening strategies for cohorts without a routine vaccination program (unvaccinated cohorts). Using A life years (LYs) and B quality-adjusted life years (QALYs) as metrics for quantifying health outcomes. Note: The thick black lines are the cost-effectiveness frontiers, with the numbers in round-cornered rectangles representing the incremental cost-effectiveness ratios compared to “no screening” (for the first non-dominated strategy, denoted with #) or the previous non-dominated strategy

Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us